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As the precursor of ﬁbrin, ﬁbrinogen plays an important role in
hemostasis [1]. Of all the components of the coagulation
system, elevated plasma ﬁbrinogen levels have most consis-
tently been shown to be associated with occlusive vascular
disorders [2–5]. Several polymorphisms in the ﬁbrinogen genes
(FGA, FGB, FGG) have been reported to be associated with
ﬁbrinogen levels. Most studies focused on FGB polymor-
phisms. However, results are not consistent and none of these
polymorphisms has been found to be associated with an
increased risk of venous [6,7] or arterial thrombosis [7].
Recently, we reported that a speciﬁc haplotype (H2) of the
ﬁbrinogen gamma gene (FGG) was associated with a 2.4-fold
increased risk of deep venous thrombosis [95% conﬁdence
intervals (CI): 1.5–3.9] [6]. In the same study, we found that
another haplotype (FGG-H3) was associated with a slight
reduction in risk [odds ratio (OR) ¼ 0.8, 95% CI: 0.6–1.0].
None of these haplotypes was associated with total ﬁbrinogen
levels. However, the FGG-H2 haplotype was associated with
reduced levels of ﬁbrinogen c¢, a product of alternative splicing
of the FGG gene. In a recent report, Mannila et al. [8] studied
the effect of haplotypes across the ﬁbrinogen gene cluster on
the risk of myocardial infarction (MI). They determined the
*216C > T polymorphism, which is identical to FGG-H2
tagging SNP 10034 C/T [rs2066865]. In their study, the FGG-
H2 haplotype was not associated with the risk ofMI. However,
they found a signiﬁcant difference in the frequency distribution
of the minor allele of the 1299 + 79T > C polymorphism
between patients and controls (0.294 vs. 0.342, P ¼ 0.04),
which suggests that this haplotype might be protective against
the development of MI. This polymorphism is identical to
FGG-H3 tagging SNP 9340 T/C [rs1049636].
The aim of the present study was to investigate the effect of
the four most common haplotypes of the FGG gene on the risk
of MI. For this study, a large population-based case–control
study, Study of Myocardial Infarctions Leiden (SMILE) was
used. Full details of the SMILE study have been described
Table 1 Variant allele and haplotype group frequencies for VKORC1 and CYP2C9 in selected populations (actual SNP locations in parentheses).
Haplotype groups A and B are based on classiﬁcations fromReider et al. [1] where haplotype A represents individuals at risk for excessive anticoagulation
with standard warfarin dosing, and haplotype B represents individuals at risk for subtherapeutic anticoagulation from standard warfarin dosing. Overall
low dose group deﬁnes individuals with at least one haplotype A and/or at least one CYP2C9 variant allele. Combined haplotype A and CYP2C9 group
deﬁnes individuals with at least one haplotype A in combination with at least one CYP2C9 variant allele. The functional signiﬁcance of haplotypes not in
group A or group B (other) is currently unknown. IVS is standard nomenclature for intronic sequence
Peruvian Mexican European–American African–American African Asian
VKORC1 861 C > A ()4451C > A) 0.04 0.15 0.33 0.12 0.04 0.02
VKORC1 5808 T > G (IVS1 + 324T > G) 0.02 0.13 0.21 0.06 0.00 0.00
VKORC1 6853 G > C (IVS2 + 124G > C) 0.31 0.49 0.37 0.22 0.25 0.91
VKORC1 9041 G > A (626G > A) 0.62 0.46 0.45 0.49 0.46 0.13
CYP2C9*2 (3608C > T) 0.00 0.06 0.14 0.02 0.01 0
CYP2C9*3 (42614A > C) 0.01 0.02 0.06 0.01 0.01 0.04
VKORC1 haplotype group A 0.27 0.38 0.42 0.21 0.23 0.85
VKORC1 haplotype group B 0.71 0.57 0.57 0.58 0.49 0.14
VKORC1 haplotype group – other 0.02 0.05 0.01 0.21 0.28 0.01
Overall low dose group 0.28 0.45 0.55 0.22 0.23 0.86
Combined haplotype A and CYP2C9 group 0.00 0.03 0.18 0.01 0.01 0.06
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elsewhere [9]. The subjects used in our previous study on
venous thrombosis [6] were all of Dutch origin and four
common haplotypes of the ﬁbrinogen gamma gene were
present in this population. Because the subjects of the SMILE
study were all Dutch men, we assumed that in the SMILE
population only these four common haplotypes would be
present. To tag these four common haplotypes, all subjects
were genotyped for three haplotype-tagging polymorphisms by
the 5¢ nuclease/TaqMan assay [10]. Polymorphism 10034 C/T
[rs2066865] tagged FGG-H2, polymorphism 9340 T/C
[rs1049636] tagged FGG-H3 and polymorphism 5836 G/A
[rs2066860] tagged FGG-H4 [6]. FGG-H1 consisted of the
common alleles of the three-mentioned polymorphisms. (Posi-
tion numbering according to SeattleSNPs [11], GenBank
Accession number AF350254).
The distribution of the genotypes among control subjects
was as expected for a population in Hardy–Weinberg equilib-
rium.No haplotypes could be assigned to four patients and two
control subjects, because of intragenic recombination. These
samples were excluded from the analyses. As shown in Table 1,
overall none of the haplotypes of the FGG gene was associated
with the risk of MI, including FGG-H2, which we found to be
a risk factor for venous thrombosis [6]. The allele frequency of
FGG-H2 was 0.276 in cases and 0.277 in control subjects. This
is in agreement with the data of Mannila et al. [8], who did not
ﬁnd an association in 377 MI patients and 387 control subjects
aged<60 years in Sweden.However, we could not conﬁrm the
reduction in risk for FGG-H3 found by Mannila et al. We
found allele frequencies of 0.298 and 0.284 for patients and
control subjects, respectively (Table 1).
Most patients with MI are middle-aged or elderly. Those
suffering MI at a younger age usually have an excess of risk
factors, including genetic factors. In men below the age of 50
(150 patients and 158 control subjects), the risk of MI was
slightly decreased for FGG-H1 (Table 1) and slightly increased
for FGG-H2. There was no effect on risk for FGG-H3 and
FGG-H4. For men aged 50 or above, there was no effect on
risk in any of the haplotypes. So, we only found a slight
increase in risk for FGG-H2 in men below the age of 50. This
might be an indication that FGG-H2 not only affects venous
thrombosis risk, but also the risk of myocardial infarction,
although the effect was weak (OR for FGG-H2H2 carriers 1.5)
with a wide CI (0.7–3.5). The sample size of this young
subgroup was relatively small and it would be useful to
investigate the role of FGG-H2 in a larger study of patients
with myocardial infarction at a young age.
Furthermore, we investigated the combined effect of FGG
haplotypes and cardiovascular risk factors such as smoking
(345 patients and 214 control subjects) or metabolic risk
factors (203 patients and 197 control subjects), in which
having a metabolic risk factor was deﬁned as the presence of
obesity, diabetes, hypertension or hypercholesterolemia [9].
The risks of the four haplotypes in the different subgroups
with or without the cardiovascular risk factors did not
change compared with the risks in the overall population. In
fact, the risks did not exceed that of the single effects of the
cardiovascular risk factors, so we did not ﬁnd evidence for
synergistic effects between FGG haplotypes and cardiovas-
cular risk factors.
In addition, we studied the relation between the FGG
haplotypes and ﬁbrinogen levels. In the control subjects,
ﬁbrinogen levels were measured in plasma using the Clauss
thrombin time method as described previously [12]. We did not
observe an association of FGG haplotypes with ﬁbrinogen
Table 1 The risk of myocardial infarction in the presence of the four most common haplotypes of the ﬁbrinogen gamma gene
Haplotype (htSNP) Patients (%) n ¼ 556 Controls (%) n ¼ 644 OR 95% CI
<50 years ‡50 years
OR 95% CI OR 95% CI
H1 (all common)
HxHx 210 (37.8) 228 (35.4) 1* 1* 1*
H1Hx 265 (47.7) 318 (49.4) 0.9 0.7–1.2 0.7 0.4–1.2 1.0 0.7–1.3
H1H1 81 (14.6) 98 (15.2) 0.9 0.6–1.3 0.7 0.4–1.4 1.0 0.6–1.5
Frequency H1 0.384 0.399
H2 (10034 C/T)
HxHx 290 (52.2) 336 (52.2) 1* 1* 1*
H2Hx 225 (40.5) 259 (40.2) 1.0 0.8–1.3 1.3 0.8–2.1 0.9 0.7–1.2
H2H2 41 (7.4) 49 (7.6) 1.0 0.6–1.5 1.5 0.7–3.5 0.8 0.5–1.4
Frequency H2 0.276 0.277
H3 (9340 T/C)
HxHx 266 (47.8) 322 (50.0) 1* 1* 1*
H3Hx 249 (44.8) 278 (43.2) 1.1 0.9–1.4 1.1 0.7–1.7 1.1 0.8–1.5
H3H3 41 (7.1) 44 (6.8) 1.1 0.7–1.8 1.1 0.4–2.9 1.2 0.7–1.9
Frequency H3 0.298 0.284
H4 (5836 G/A)
HxHx 509 (91.5) 593 (92.1) 1* 1* 1*
H4Hx 47 (8.5) 51 (7.9) 1.1 0.7–1.6 0.9 0.4–2.1 1.2 0.7–1.8
H4H4 – – – – – – – –
Frequency H4 0.042 0.040
*Reference category.
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levels in these control subjects. This is consistent with a
previous study in which we did not ﬁnd an association of these
haplotypes with ﬁbrinogen levels in the 473 control subjects of
the Leiden Thrombophilia Study [6].
We conclude that none of the four common haplotypes of
the FGG gamma gene has a strong effect on the risk of MI.
Homozygosity for FGG-H2, which we found previously to be
a risk factor for venous thrombosis, might slightly increase the
risk ofMI in patients younger than 50 years. These ﬁndings are
in line with the studies on other prothrombotic factors that
affect the risk of venous thrombosis but have small or no effects
on arterial disease [13].
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Statins modulate expression of components of the plasminogen
activator/plasmin system in human cardiac myocytes in vitro
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Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors or statins represent an established class of drugs for
the treatment of hypercholesterolemia and large-scale clinical
trials have emphasized their beneﬁts in the primary and
secondary prevention of myocardial infarction (MI) through
their positive effects on atherosclerosis and its complications
[1–3]. Recent ﬁndings that the statins attenuate myocardial
hypertrophy in vitro and in vivo provide evidence that these
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